[Reporter's view] Paid-in capital increase & bio ventures
By Lee, Seok-Jun | translator Kim, Jung-Ju
23.09.25 05:50:13
가나다라
0
Bio ventures have recently begun to raise funds through paid-in capital increases allotted to shareholders as promised. This is a phenomenon that has recently emerged as the bio market is not doing well, making it difficult to attract investment from institutional investors such as VCs (venture capitals) or specific third parties. Shareholders express the current situation as a ‘crying train’. Even though there is a high possibility that the stock price will fall, it is because of the worry.
Just looking at the past three to four months, there are numerous bio ventures that have completed or are in the process of capital increase. CJ Bioscience, PCL, SCM Life Science, Cellid, Voronoi, SD Biosensor, and N
Lee, Seok-Jun(wiviwivi@dailypharm.com)
If you want to see the full article, please JOIN US (click)